Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.

Autor: Umesh G Lalloo, Lauren Komarow, Judith A Aberg, David B Clifford, Evelyn Hogg, Ashley McKhann, Aggrey Bukuru, David Lagat, Sandy Pillay, Vidya Mave, Khuanchai Supparatpinyo, Wadzanai Samaneka, Deborah Langat, Eduardo Ticona, Sharlaa Badal-Faesen, Robert A Larsen, ACTG A5225 Team

Publikováno v: PLoS ONE, Vol 18, Iss 2, p e0281580 (2023)

BackgroundThe WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determ

Externí odkaz: https://doaj.org/article/d5c2b08341f74d62a664c9a9098c7601

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Autor: Marije Van Schalkwyk, Lerato Mohapi, R Luk, Peter Mugyenyi, RT Schooley, SN Fontain, Beatriz Grinsztejn, Cecilia Kanyama, T Sise, A Collier, R Salata, J Valencia, P Sugandhavesa, BR Santos, Patcharaphan Sugandhavesa, Carole L. Wallis, Breno Santos, R Walensky, R Gross, H Mugerwa, SW Cardoso, J Rooney, Justin Ritz, L Hovind, Sharlaa Faesen, Robert E. Gross, CV Fletcher, L Wieclaw, Evelyn Hogg, A Shahkolahi, M van Schalkwyk, W Samaneka, Y van Delft, John W. Mellors, S Faesen, C Wallis, Aggrey Bukuru, Robert T. Schooley, Anchalee Avihingsanon, N Kumarasamy, J van Wyk, D Kadam, C Godfrey, R Leavitt, Ann C. Collier, R Secours, C Kanyama, Mumbi Makanga, L Nakibuuka, H Nassolo, Wadzanai Samaneka, M Gandhi, Esmelda Montalban, R Mngqibisa, Javier Valencia, P Anthony, Vidya Mave, Rosie Mngqibisa, V Kulkarni, E Hogg, Nagalingeswaran Kumarasamy, V Mave, Robert A. Salata, Catherine Godfrey, A Benns, M Hughes, A Avihingsanon, B Grinsztejn, B Mansfield, PN Mugyenyi, M Nsubuga, M Makanga, Michael Hughes, Sandra W. Cardoso, J Ritz, Linda Wieclaw, Rode Secours, Sandy Nerette Fontain, Beatrice Wangari Ndege, BW Ndege, E Montalban

Publikováno v: Lancet HIV

Summary Background Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f078ada1a0d0932b29304d8b17fbc82
https://pubmed.ncbi.nlm.nih.gov/31371262

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

Autor: Fred, Kyeyune, Immaculate, Nankya, Samar, Metha, Juliet, Akao, Emmanuel, Ndashimye, Denis M, Tebit, Benigno, Rodriguez, Cissy, Kityo, Robert A, Salata, Peter, Mugyenyi, Eric, Arts, Aggrey, Bukuru

Publikováno v: AIDS (London, England). 27(12)

To determine the impact of HIV-1 subtype on treatment outcomes and the emergence of drug resistance in the resource limited setting of Kampala, Uganda.The Joint Clinical Research Centre (JCRC) in Kampala, Uganda has provided over 2000 drug-resistant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c771d9133df0d342782a553ae545aa
https://pubmed.ncbi.nlm.nih.gov/23727942